This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -54.05% and 2.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 10.45% and 2.12%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Synlogic, Inc. (SYBX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Synlogic, Inc. (SYBX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Synlogic, Inc. (SYBX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 19.23% and 80.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 21.74% and 39.60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Synlogic, Inc. (SYBX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 8% and 3.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
SQZ Biotechnologies Company (SQZ) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
SQZ Biotechnologies Company (SQZ) delivered earnings and revenue surprises of -11.11% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Synlogic, Inc. (SYBX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Synlogic, Inc. (SYBX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Synlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 7.69% and 73.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of 12.50% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of 10.34% and 12.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Synlogic, Inc. (SYBX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Synlogic, Inc. (SYBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Synlogic, Inc. (SYBX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Synlogic, Inc. (SYBX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 4.35% and 49.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Certara, Inc. (CERT) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Certara, Inc. (CERT) delivered earnings and revenue surprises of -18.18% and 3.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of 0% and 1.40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Synlogic, Inc. (SYBX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 4.35% and 51.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Synlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 22.22% and 1.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
What Makes Synlogic, Inc. (SYBX) a New Buy Stock
by Zacks Equity Research
Synlogic, Inc. (SYBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AbbVie's (ABBV) Skyrizi Gets Nod for Psoriatic Arthritis in EU
by Zacks Equity Research
AbbVie (ABBV) secures approval in the EU for Skyrizi to treat adult patients with active psoriatic arthritis.
Novavax (NVAX) COVID Jab Gets Philippines Nod, Under Review in EU
by Zacks Equity Research
Novavax's (NVAX) secures approval for its COVID vaccine in the Philippines. The EMA begins reviewing the company's regulatory submission for its COVID vaccine. Evidently, the stock gains.
CRISPR (CRSP) to Begin Clinical Study on Diabetes Therapy Drug
by Zacks Equity Research
CRISPR Therapeutics (CRSP) receives clearance from Health Canada to initiate clinical studies for VCTX210, its investigational therapy for the treatment of type 1 diabetes.
Synlogic, Inc. (SYBX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 0.00% and 233.09%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Axsome (AXSM) Q3 Earnings Top, Pre-Launch Activities Continue
by Zacks Equity Research
Axsome Therapeutics (AXSM) reports a narrower-than-expected Q3 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.
BioMarin (BMRN) Phenylketonuria Gene Therapy on Clinical Hold
by Zacks Equity Research
BioMarin's (BMRN) phase I/II study on gene therapy candidate, BMN 307, has been placed under a clinical hold by the FDA possibly on malignancy concerns.